$155.21
1.06% day before yesterday
NYSE, May 30, 10:12 pm CET
ISIN
US4781601046
Symbol
JNJ

Johnson & Johnson Stock price

$155.21
-1.10 0.70% 1M
+0.41 0.26% 6M
+10.59 7.32% YTD
+9.93 6.84% 1Y
-25.88 14.29% 3Y
+8.02 5.45% 5Y
+55.17 55.15% 10Y
NYSE, Closing price Fri, May 30 2025
+1.63 1.06%
ISIN
US4781601046
Symbol
JNJ
Sector
Industry

Key metrics

Market capitalization $373.45b
Enterprise Value $386.92b
P/E (TTM) P/E ratio 17.26
EV/FCF (TTM) EV/FCF 18.99
EV/Sales (TTM) EV/Sales 4.33
P/S ratio (TTM) P/S ratio 4.18
P/B ratio (TTM) P/B ratio 4.78
Dividend yield 3.16%
Last dividend (FY24) $4.91
Revenue growth (TTM) Revenue growth 4.30%
Revenue (TTM) Revenue $89.33b
EBIT (operating result TTM) EBIT $23.37b
Free Cash Flow (TTM) Free Cash Flow $20.37b
Cash position $38.78b
EPS (TTM) EPS $8.99
P/E forward 14.18
P/S forward 4.09
EV/Sales forward 4.24
Short interest 0.95%
Show more

Create a Free Account to create an Johnson & Johnson alert.

Set up alerts on Stock Price, Dividend Yield, Valuation (e.g. P/E or EV/Sales) or Strategy Scores and sit back and relax.

Johnson & Johnson Stock Analysis

Unlock Scores for Free

Analyst Opinions

25 Analysts have issued a Johnson & Johnson forecast:

11x Buy
44%
14x Hold
56%

Analyst Opinions

25 Analysts have issued a Johnson & Johnson forecast:

Buy
44%
Hold
56%

Financial data from Johnson & Johnson

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
89,331 89,331
4% 4%
100%
- Direct Costs 28,281 28,281
9% 9%
32%
61,050 61,050
2% 2%
68%
- Selling and Administrative Expenses 22,724 22,724
4% 4%
25%
- Research and Development Expense 16,915 16,915
11% 11%
19%
30,668 30,668
3% 3%
34%
- Depreciation and Amortization 7,296 7,296
2% 2%
8%
EBIT (Operating Income) EBIT 23,372 23,372
4% 4%
26%
Net Profit 21,810 21,810
43% 43%
24%

In millions USD.

Don't miss a Thing! We will send you all news about Johnson & Johnson directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Johnson & Johnson Stock News

Positive
Seeking Alpha
2 days ago
Johnson & Johnson remains undervalued with strong profitability and reasonable valuation metrics, but growth prospects are modest and uncertain. Profitability is robust, with an A+ grade, high margins, and nearly 30% return on equity, supporting the company's structural quality. Key risks include regulatory challenges, legal liabilities from talc lawsuits, and potential price controls on major ...
Neutral
24/7 Wall Street
2 days ago
It may be too soon to rotate back into the risk trade as market volatility calms.
Neutral
Business Wire
4 days ago
NEW BRUNSWICK, N.J.--(BUSINESS WIRE)--Johnson & Johnson (NYSE: JNJ) will host a conference call for investors at 8:30 a.m. (Eastern Time) on Wednesday, July 16th to review second-quarter results. Joaquin Duato, Chairman and Chief Executive Officer, Joseph J. Wolk, Executive Vice President and Chief Financial Officer and Darren Snellgrove, Vice President, Investor Relations will host the call. T...
More Johnson & Johnson News

Company Profile

Johnson & Johnson is a holding company, which engages in the research and development, manufacture and sale of products in the health care field. It operates through the following segments: Consumer, Pharmaceutical, and Medical Devices. The Consumer segment includes products used in the baby care, oral care, beauty, over-the-counter pharmaceutical, women's health, and wound care markets. The Pharmaceutical segment focuses on therapeutic areas such as immunology, infectious diseases ad vaccines, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. The Medical Devices segment offers products used in the orthopedic, surgery, cardiovascular, diabetes care, and eye health fields. The company was founded by Robert Wood Johnson I, James Wood Johnson and Edward Mead Johnson Sr. in 1886 and is headquartered in New Brunswick, NJ.

Head office United States
CEO Joaquin Duato
Employees 138,100
Founded 1887
Website www.jnj.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today